Top

Published in:

01-04-2016 | Original Article

Upregulation of long noncoding RNA TMEVPG1 enhances T helper type 1 cell response in patients with Sjögren syndrome

Authors: Juan Wang, Huiyong Peng, Jie Tian, Jie Ma, Xinyi Tang, Ke Rui, Xinyu Tian, Yungang Wang, Jianguo Chen, Liwei Lu, Huaxi Xu, Shengjun Wang

Published in: Immunologic Research | Issue 2/2016

Abstract

Long noncoding RNAs (lncRNA) play key roles in regulating autoimmunity and immunity balance. LncRNA TMEVPG1, which is encoded by a gene located near the Ifn gene, contributes to interferon gamma expression. We investigated the expression of TMEVPG1 in patients with Sjögren syndrome (SS) to determine its role in the pathogenesis of SS. In this study, we detected the relative expression of TMEVPG1 in CD4⁺ T cells of 25 SS patients and 25 healthy donors. Moreover, the proportion of Th1 cells and T-bet levels was also analyzed. Furthermore, we explored the correlation between the expression of TMEVPG1 and the level of autoantibodies, erythrocyte sedimentation rate (ESR) and IgG in SS patients. Our results indicated that the proportion of Th1 cells and the levels of TMEVPG1 and T-bet were increased in SS patients. In addition, the level of expression of TMEVPG1 was correlated with the level of SSA, ESR and IgG. Our data suggest that upregulation of lncRNA TMEVPG1 may be involved in the pathogenesis of Sjögren syndrome.

Singh N, Cohen PL. The T cell in Sjögren’s syndrome: force majeure, not spectateur. J Autoimmun. 2012;39(3):229–33.CrossRefPubMedPubMedCentral

Fox RI, Kang HI, Ando D, et al. Cytokine mRNA expression in salivary gland biopsies of Sjögren’s syndrome. J Immunol. 1994;152:5532–9.PubMed

Boumba D, Skopouli FN, Moutsopoulos HM. Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjögren’s syndrome. Br J Rheumatol. 1995;34:326–33.CrossRefPubMed

Kolkowski EC, Reth P, Pelusa F, et al. Th1 predominance and perforin expression in minor salivary glands from patients with primary Sjögren’s syndrome. J Autoimmun. 1999;13(1):155–62.CrossRefPubMed

Li X, Xu B, Wang Y, et al. Anti-inflammatory effect of peroxisome proliferator-activated receptor-γ (PPAR-γ) on non-obese diabetic mice with Sjögren’s syndrome. Int J Clin Exp Pathol. 2014;7(8):4886–94.PubMedPubMedCentral

Cha S, Brayer J, Gao J, et al. A dual role for interferon-gamma in the pathogenesis of Sjögren’s syndrome-like autoimmune exocrinopathy in the nonobese diabetic mouse. Scand J Immunol. 2004;60(6):552–65.CrossRefPubMed

Lin X, Rui K, Deng J, et al. Th17 cells play a critical role in the development of experimental Sjögren’s syndrome. Ann Rheum Dis. 2015;74(6):1302–10.CrossRefPubMed

Peng H, Liu Y, Tian J, et al. Decreased expression of microRNA-125a-3p upregulates interleukin-23 receptor in patients with Hashimoto’s thyroiditis. Immunol Res. 2015;62(2):129–36.CrossRefPubMed

Chen J, Tian J, Tang X, et al. MiR-346 regulates CD4⁺ CXCR5⁺ T cells in the pathogenesis of Graves’ disease. Endocrine. 2015;49(3):752–60.CrossRefPubMed

10.

Pauley KM, Stewart CM, Gauna AE, et al. Altered miR-146a expression in Sjögren syndrome and its functional role in innate immunity. Eur J Immunol. 2011;41(7):2029–39.CrossRefPubMedPubMedCentral

11.

Spierings DC, McGoldrick D, Hamilton-Easton AM, et al. Ordered progression of stage-specific miRNA profiles in the mouse B2 B-cell lineage. Blood. 2011;117(20):5340–9.CrossRefPubMedPubMedCentral

12.

Chiyomaru T, Fukuhara S, Saini S, et al. Long non-coding RNA HOTAIR is targeted and regulated by miR-141 in human cancer cells. J Biol Chem. 2014;289(18):12550–65.CrossRefPubMedPubMedCentral

13.

Van Roosbroeck K, Pollet J, Calin GA. MiRNAs and long noncoding RNAs as biomarkers in human diseases. Expert Rev Mol Diagn. 2013;13(2):183–204.CrossRefPubMed

14.

Mourtada-Maarabouni M, Hasan AM, Farzaneh F, et al. Inhibition of human T-cell proliferation by mammalian target of rapamycin (mTOR) antagonists requires noncoding RNA growth-arrest-specific transcript 5 (GAS5). Mol Pharmacol. 2010;78(1):19–28.CrossRefPubMedPubMedCentral

15.

Gomez JA, Wapinski OL, Yang YW, et al. The NeST long ncRNA controls microbial susceptibility and epigenetic activation of the interferon-γ locus. Cell. 2013;152(4):743–54.CrossRefPubMedPubMedCentral

16.

Collier SP, Collins PL, Williams CL, et al. Cutting edge: influence of TMEVPG1, a long intergenic noncoding RNA, on the expression of Ifng by Th1 cells. J Immunol. 2012;189(5):2084–8.CrossRefPubMedPubMedCentral

17.

Collier SP, Henderson MA, Tossberg JT, et al. Regulation of the Th1 genomic locus from Ifn-g. through Tmevpg1 by T-bet. J Immunol. 2014;193(8):3959–65.CrossRefPubMedPubMedCentral

18.

Jonsson R, Vogelsang P, Volchenkov R, et al. The complexity of Sjögren’s syndrome: novel aspects on pathogenesis. Immunol Lett. 2011;141(1):1–9.CrossRefPubMed

19.

Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American- European Consensus Group. Ann Rheum Dis. 2002;61(6):554–8.CrossRefPubMedPubMedCentral

20.

Vasudevan A, Bhide PG. Angiogenesis in the embryonic CNS: a new twist on an old tale. Cell Adh Migr. 2008;2(3):167–9.CrossRefPubMedPubMedCentral

21.

Hernandez-Molina G, Leal-Alegre G, Michel-Peregrina M. The meaning of anti-Ro and anti-La antibodies in primary Sjögren’s syndrome. Autoimmun Rev. 2011;10(3):123–5.CrossRefPubMed

22.

Khalil AM, Guttman M, Huarte M, et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA. 2009;106(28):11667–72.CrossRefPubMedPubMedCentral

23.

Guttman M, Amit I, Garber M, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009;458(7235):223–7.CrossRefPubMedPubMedCentral

24.

Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet. 2006; 15 Spec No 1:R17-29.

25.

Jimenez SA, Piera-Velazquez S. Potential role of human-specific genes, human-specific microRNAs and human-specific non-coding regulatory RNAs in the pathogenesis of systemic sclerosis and Sjögren syndrome. Autoimmun Rev. 2013;12(11):1046–51.CrossRefPubMedPubMedCentral

26.

Vigneau S, Rohrlich PS, Brahic M, et al. Tmevpg1, a candidate gene for the control of Theiler’s virus persistence, could be implicated in the regulation of gamma interferon. J Virol. 2003;77(10):5632–8.CrossRefPubMedPubMedCentral

27.

Gonzalez-Navajas JM, Lee J, David M, et al. Immunomodulatory functions of type I interferons. Nat Rev Immunol. 2012;12(2):125–35.PubMedPubMedCentral

28.

Li H, Ice JA, Lessard CJ, et al. Interferons in Sjögren’s syndrome: genes, mechanisms, and effects. Front Immunol. 2013;4:290.PubMedPubMedCentral

29.

Hjelmervik TO, Petersen K, Jonassen I, et al. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren’s syndrome patients from healthy control subjects. Arthritis Rheum. 2005;52(5):1534–44.CrossRefPubMed

30.

Hall JC, Baer AN, Shah AA, et al. Molecular subsetting of interferon pathways in Sjögren’s syndrome. Arthriti Rheumatol. 2015;67(9):2437–46.CrossRef

31.

Nguyen CQ, Peck AB. The interferon-signature of Sjögren’s syndrome: how unique biomarkers can identify underlying inflammatory and immunopathological mechanisms of specific diseases. Front Immunol. 2013;4:142.CrossRefPubMedPubMedCentral

32.

Hall JC, Casciola-Rosen L, Berger AE, et al. Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proc Natl Acad Sci USA. 2012;109(43):17609–14.CrossRefPubMedPubMedCentral

33.

Hertzog P, Forster S, Samarajiwa S. Systems biology of interferon responses. J Interferon Cytokine Res. 2011;31(1):5–11.CrossRefPubMed

34.

Nezos A, Gravani F, Tassidou A, et al. Type I and II interferon signatures in Sjögren’s syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjögren’s related lymphomagenesis. J Autoimmun. 2015;S0896–8411(15):30006–8.

35.

Ogawa N, Li P, Li Z, et al. Involvement of the interferon-gamma-induced T cell-attracting chemokines, interferon-gamma-inducible 10-kd protein (CXCL10) and monokine induced by interferon-gamma (CXCL9), in the salivary gland lesions of patients with Sjögren’s syndrome. Arthritis Rheum. 2002;46:2730–41.CrossRefPubMed

Title: Upregulation of long noncoding RNA TMEVPG1 enhances T helper type 1 cell response in patients with Sjögren syndrome
Authors: Juan Wang
Huiyong Peng
Jie Tian
Jie Ma
Xinyi Tang
Ke Rui
Xinyu Tian
Yungang Wang
Jianguo Chen
Liwei Lu
Huaxi Xu
Shengjun Wang
Publication date: 01-04-2016
Publisher: Springer US
Published in: Immunologic Research / Issue 2/2016
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-015-8715-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Upregulation of long noncoding RNA TMEVPG1 enhances T helper type 1 cell response in patients with Sjögren syndrome

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

Interaction of TIM4 and TIM3 induces T helper 1 cell apoptosis

Human neutrophil peptide-1 decreases during ageing in selected Mexican population

Soluble mediators produced by the crosstalk between microvascular endothelial cells and dengue-infected primary dermal fibroblasts inhibit dengue virus replication and increase leukocyte transmigration

Induction of proteinase 3-anti-neutrophil cytoplasmic autoantibodies by proteinase 3-homologous bacterial protease in mice

Epigenetic control of the immune system: a lesson from Kabuki syndrome

Membrane array and multiplex bead analysis of tear cytokines in systemic sclerosis